Accelerating glioblastoma therapeutics via venture philanthropy
Author(s)
Siah, Kien Wei; Xu, Qingyang; Tanner, Kirk; Futer, Olga; Frishkopf, John J; Lo, Andrew W; ... Show more Show less
DownloadPublished version (288.4Kb)
Publisher with Creative Commons License
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
Development of curative treatments for glioblastoma (GBM) has been stagnant in recent decades largely because of significant financial risks. A portfolio-based strategy for the parallel discovery of breakthrough therapies can effectively reduce the financial risks of potentially transformative clinical trials for GBM. Using estimates from domain experts at the National Brain Tumor Society (NBTS), we analyze the performance of a portfolio of 20 assets being developed for GBM, diversified across different development phases and therapeutic mechanisms. We find that the portfolio generates a 14.9% expected annualized rate of return. By incorporating the adaptive trial platform GBM AGILE in our simulations, we show that at least one drug candidate in the portfolio will receive US Food and Drug Administration (FDA) approval with a probability of 79.0% in the next decade.
Date issued
2021Department
Sloan School of Management. Laboratory for Financial Engineering; Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science; Massachusetts Institute of Technology. Operations Research CenterJournal
Drug Discovery Today
Publisher
Elsevier BV
Citation
Siah, Kien Wei, Xu, Qingyang, Tanner, Kirk, Futer, Olga, Frishkopf, John J et al. 2021. "Accelerating glioblastoma therapeutics via venture philanthropy." Drug Discovery Today, 26 (7).
Version: Final published version